This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
7/10/14 11:54AM
Even with greater decline in walk performance after almost three years, Duchenne boys treated with eteplirsen are still benefiting from treatment, Sarepta says.
7/10/14 8:31AM
The SEC halts trading in Radient Pharmaceuticals.
7/8/14 9:52AM
Provectus Biopharmaceuticals issued a "CEO Letter" Tuesday regurgitating all the recent spin and ridiculously unrealistic talking points about the company's experimental (but already obsolete) melanoma therapy PV-10.
7/8/14 9:14AM
Sarepta is selling off Monday on new worries about eteplirsen efficacy. Of course, these are really just old worries, recycled.
7/7/14 2:49PM
Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.
7/7/14 11:23AM
The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.
6/25/14 1:05PM
Investors aren't yet recognizing Vertex's ability to develop triple-combo therapies for hardest-to-treat cystic fibrosis patients.
6/25/14 11:26AM
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.
6/24/14 12:07PM
Combination therapy of two Vertex Pharmaceuticals drugs hit a big mark in the treatment of cystic fibrosis.
6/24/14 10:02AM
Based on positive study results, Vertex will seek approval for the cystic fibrosis regimen of VX-809 and Kalydeco in the fourth quarter.
6/24/14 7:25AM
MD Anderson released a statement criticizing Northwest Bio on Friday night after company shareholders and supporters flamed the hospital's Facebook page with hateful comments.
6/23/14 9:05AM
Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.
6/20/14 9:41AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
6/20/14 8:03AM
Northwest Bio has issued five press releases and held a conference call in the past month to disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct. But investigators at MD Anderson and the two other hospitals conducting the DCVax-Direct study have not reviewed or analyzed data at all because patients are still being enrolled and treated.
6/19/14 8:46AM
Let's wind back the tape more than 9 years to documents the many instances in which MannKind executives made promises about partnering the inhaled insulin Afrezza.
6/17/14 2:25PM
Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by Bluebird Bio, according to new but preliminary data presented Saturday.
6/16/14 7:28AM
Bernstein analyst Geoff Porges hung out with doctors and cystic fibrosis experts at the just-concluded European Cystic Fibrosis Society conference in Sweden and returned home even more bearish on Vertex Pharmaceuticals. In a research note Monday, Porges lays out reasons why the super-important combination studies of Kalydeco and VX-809 -- TRAFFIC and TRANPORT -- are more likely to fail.
6/16/14 7:01AM
Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by Bluebird Bio BLUE, according to new but preliminary data presented Saturday.
6/14/14 10:16AM
Galena is paying a marketing firm to create promotions for its experimental breast cancer vaccine Neuvax. These Neuvax ads are dressed up to like legitimate news articles, except for the small disclaimer labeling them as "sponsored content paid for by a third party..."
6/13/14 10:11AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
6/13/14 8:00AM
EnteroMedics and its VBLOC "fat-zapping" implantable medical device will be the focus of an FDA advisory panel meeting next Tuesday, June 17. If FDA follows historical form, the agency's review of VBLOC's safety and efficacy will be available publicly tomorrow morning.
6/12/14 8:00AM
FDA needs more time to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of heart-safety related outcomes for Contrave, Orexigen said
6/11/14 6:48AM
Inovio Pharmaceuticals CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from the VGX-3100 study should be announced any day, but I suspect Inovio already has data in hand. Why else would Kim be laying the foundation for a massive spin job, if not to cushion the vaccine's failure?
6/10/14 12:23PM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs